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Abstract
RNA and DNA aptamers specific for HIV-1 reverse transcriptase (RT) can inhibit reverse
transcription in vitro. RNA aptamers have been shown to potently block HIV-1 replication in
culture. We previously reported mutants of HIV-1 RT with substitutions N255D or N265D that
display resistance to the DNA aptamer RT1t49. Variant viruses bearing these mutations singly or
in combination were compromised for replication. In order to address the wider applicability of
such aptamers, HIV-1 RT variants containing the N255D, N265D or both (Dbl) were tested for
the extent of their cross-resistance to other DNA/RNA aptamers as well as to other RT inhibitors.
Both N265D and Dbl RTs were resistant to most aptamers tested. N255D mutant displayed mild
resistance to two of the DNA aptamers, little change in sensitivity to three and hypersensitivity to
one. Although all mutants displayed wild type-like ribonuclease H activity, their activity was
compromised under conditions that prevent re-binding. This suggests that the processivity defect
caused by these mutations can also affect RNase H function thus contributing further to the
replication defect in mutant viruses. These results indicate that mutants conferring resistance to
anti-RT aptamers significantly affect many HIV-1 RT enzymatic activities, which could contribute to
preventing the development of resistance in vivo. If such mutations were to arise in vivo, our results
suggest that variant viruses should remain susceptible to many existing anti-RT inhibitors. This
result was tempered by the observation that NRTI-resistance mutations such as K65R can confer
resistance to some anti-RT aptamers.
Background
The reverse transcriptase (RT) of the human immunodefi-
ciency virus type 1 (HIV-1) is a multifunctional enzyme,
capable of several discrete activities required for viral rep-
lication [1]. These essential activities include DNA- and
RNA-dependent DNA polymerase (DDDP and RDDP),
ribonuclease H (RNase H), strand transfer and strand dis-
placement activities. Native HIV-1 RT is a heterodimer of
p66 and p51 subunits, of which the p66 subunit contains
both the polymerase and RNase H domains. The p51 sub-
unit is derived by proteolytic cleavage of the p66 subunit
and is thought to play both an architectural role in the
context of the p66/p51 heterodimer as well as facilitate
template·primer binding [2].
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Due to its essential role in synthesizing the double-
stranded proviral DNA from single-stranded HIV-1 RNA
genome, the HIV-1 RT is a major target of current antiviral
therapies directed against HIV-1. Current anti-HIV drug
regimens, termed highly active antiretroviral therapy
(HAART), typically consist of a combination of at least
three antiretroviral drugs, with two or more nucleotide
reverse transcriptase inhibitors (NRTIs) being a staple of
most regimens [3,4]. In addition to NRTIs, which are both
competitive inhibitors and chain-terminators, the non-
nucleoside reverse transcriptase inhibitors (NNRTIs) con-
sist of structurally dissimilar hydrophobic compounds
that bind to a hydrophobic pocket on the RT adjacent to,
but distinct from, the active site, which accommodates
dNTPs and NRTIs. While HAART regimens have decreased
both the mortality and morbidity of HIV-infected individ-
uals, several factors contribute to drug failure. The highly
error-prone nature of HIV-1 RT [5,6] combined with a
robust rate of viral replication [7,8] provides the virus
with an ideal context for the emergence of resistant vari-
ants. In addition, the significant toxicity associated with
the current crop of anti-HIV drugs often leads to noncom-
pliance, which in turn results in treatment failure [9]. For
these reasons, there is a high level of interest in the devel-
opment of more potent anti-HIV inhibitors that are both
less likely to lead to drug-resistant variants and display
less toxicity in patients.
Among a number of anti-HIV agents being developed for
potential use in the treatment of AIDS are nucleic acid-
based inhibitors that can serve as useful complementary
therapies [10]. Of these, three nucleic acid-based
approaches have recently been shown to have potent
influence on HIV replication. In one, using a long anti-
sense env RNA approach, strong inhibition of HIV replica-
tion was observed in cultured T cells [11]. This approach
combined with a lentiviral vector completed the phase I
clinical trials and is about to enter phase II trials [12]. The
second approach, RNA interference (RNAi), uses a natural
cellular pathway for gene silencing via small interfering
RNAs [13-16]. The third approach is based on DNA and
RNA aptamers that are derived by the iterative process of
SELEX, to bind to specific protein targets [17] and has
been recently shown to be effective in blocking HIV repli-
cation [18-20].
Tuerk and Gold first reported the isolation of RNA aptam-
ers targeting HIV-1 RT using an iterative selection process
of binding, washing and eluting the RNAs from a random
library of RNA sequences [21]. Subsequent reports
showed that both DNA and RNA aptamers generated
against HIV-1 RT [22,23] are highly specific (do not bind
to FIV or MuLV RTs), bind tightly to HIV-1 RT (Kd in the
range of 0.05 to 50 nM) and competitively inhibit its
polymerase activity. The crystal structure of an HIV-1 RT
complexed with an anti-RT aptamer confirmed that the
aptamer RNA is bound by the template·primer cleft of
HIV RT [24]. Since these aptamers compete with tem-
plate·primer for the template-binding cleft, they have
been termed template analog RT inhibitors (TRTIs) [25].
In order to test the utility of anti-RT aptamers as inhibitors
of HIV replication, we previously expressed RNA aptamers
specific to HIV-1 RT in Jurkat T cells and showed that the
tightest binding aptamers were able to potently block the
infection and the subsequent spread of HIV-1 in cell cul-
ture [19]. In addition, five of the nine different clades of
HIV-1 tested and all of the RTI and PI-resistant isolates
tested were also severely inhibited [19]. The block was
found to be in the early steps of reverse transcription. A
subsequent report, using single cycle infection experi-
ments involving one RNA aptamer (1.1), has confirmed
the strong inhibition of HIV-1 replication by anti-RT
aptamers [18].
It has been suggested that resistance to aptamers in vivo
may be difficult due to the presumed need for multiple
mutations required to disengage the interactions via the
large interface between the inhibitor and HIV-1 RT [19].
In order to address this notion, we previously used a phe-
notypic screen based on the in situ detection of RNA-
dependent DNA polymerase activity of HIV-1 RT
expressed within bacterial colonies, and isolated two var-
iants of recombinant HIV-1 RT bearing the substitutions
N255D or N265D, both of which displayed in vitro resist-
ance to the DNA aptamer RT1t49 [25]. The mechanism of
resistance to these aptamers appeared to be based on the
loss of affinity to the aptamer and the level of resistance
increased from a range of 2- to 11-fold for single muta-
tions to ~150-fold when the two mutations were com-
bined. When the mutant RT sequences were incorporated
into molecular clones of HIV-1, the resulting HIV virions
were compromised for infectivity in single cycle infection
assays and for virus replication in multi-day cell culture
replication experiments [25]. Thus, despite the biochemi-
cally robust enzymatic activity that allows one to measure
drug-susceptibility levels of the mutant RTs, it appeared
that the aptamer-resistance mutations tend to target bio-
logically crucial sites. In support of this view, we have fur-
ther demonstrated that all three mutants (the N255D,
N265D and the double mutant (Dbl) RTs containing both
mutations) are defective for processive DNA-dependent
DNA polymerase activity (DDDP), although N265D
retained processive polymerization activity on RNA tem-
plates [26].
The data available demonstrate the utility of aptamers in
inhibiting HIV-1 replication. In addition to their exquisite
specificity, high level of resistance to anti-RT aptamers
appears to require multiple mutations, which affect the
polymerase activity of the enzyme. Although resistantAIDS Research and Therapy 2005, 2:8 http://www.aidsrestherapy.com/content/2/1/8
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virus particles could be produced from molecular clones
with mutant RTs, the mutant viruses displayed reduced
replication competence and thus lacked a competitive
edge in the presence of a large complexity of virus popu-
lation. It is important to know whether the aptamer-resist-
ant RTs retain their sensitivity to other classes of anti-RT
drugs. In the present communication, we have further
evaluated the enzymatic properties of the aptamer-resist-
ant RTs. First, we measured the breadth of cross-resistance
to other anti-RT inhibitors, including several standard
NRTIs and NNRTIs and otherDNA and RNA aptamers
specific to HIV-1 RT. Second, we have investigated bio-
chemical defects that may be responsible for their reduced
replication fitness. These are important questions con-
cerning the potential of anti-RT aptamers as a viable treat-
ment option. We find that these mutants are resistant to
several additional DNA aptamers, thus suggesting a com-
mon contact point on HIV-1 RT to this new class of
nucleic acid-based anti-RT inhibitors. Importantly, we
find that the aptamer-resistant mutations retain wild-type
susceptibilities to all NRTIs and NNRTIs tested. Further-
more, amongst a series of NRTI-resistant HIV-1 RT vari-
ants, only the K65R RT mutant displayed a significant (5-
fold) level of resistance to RT1t49. Our results, combined
with previous reports, demonstrate that mutations confer-
ring resistance to the DNA aptamer, RT1t49 in vitro affect
Table 1: Resistance of Purified RTs to DNA and RNA Aptamers. Assays were performed as described previously [34]. Data represent 
mean ± SEM of three independent experiments.
WT N255D N265D Dbl
aTRTI bIC50, nM cRatio IC50, nM Ratio IC50, nM Ratio IC50, nM Ratio
RT1t49d 
RT26f
1.6 
4.0 ± 0.05
1
1
7.9
7.6 ± 0.1
4.9
1.9
17.4
11.2 ± 0.1
10.9
2.8
245
24 ± 0.1
153
6
RT4f 38 ± 1.2 1 80 ± 3.7 2.1 1015 ± 16 27 > 1000 > 27e
RT6f 19.6 ± 0.1 1 26 ± 0.7 1.3 87 ± 2.2 4.4 142 ± 3.4 7.2
RT8f 19.5 ± 0.3 1 2.0 ± 0.02 0.1 17.2 ± 0.2 0.9 3.0 ± 0.02 0.1
RT10f 82 ± 2.5 1 57 ± 1.4 0.7 923 ± 8.9 11 509 ± 4.2 6
Rknot 1.1f 1.4 ± 0.02 1 0.8 ± 0.01 0.8 2.5 ± 0.04 2 4.5 ± 0.08 4
aDescribed in references 23 and 25.
bConcentration of aptamer at which 50% of the activity was inhibited.
cFold increase or decrease over the IC50 for the wild type (WT) RT.
dReproduced from Fisher et al. [25] eAt the highest concentration of aptamer tested (1000 nM), the Dbl mutant retained 70% of its activity, thus the 
actual IC50 would be much higher.
fAptamer sequences: RT1t49: 5' ATCCGCCTGATTAGCGATACTCAGAAGGATAAACTGTCCAGAACTTGGA3'
RT26: 5'ATCCGCCTGATTAGCGATACTTACGTGAGCGTGCTGTCCCCTAAAGGTGATACGTCACTTGAGCAAAATC ACCTGCAGGGG3'
RT4:5'ATCCGCCTGATTAGCGATACTTTAGCAAAGTTGAAGCCGGACTAACAAGCTCTACGACTTGAGCAAAATCA CCTGCAGGGG3'
RT6: 5'ATCCGCCTGATTAGCGATACTCAGGCGTTAGGGAAGGGCGTCGAAAGCAGGGTGGGACTTGAGCAAAATCA CCTGAGGGG3'
RT8:5'ATCCGCCTGATTAGCGATACTAGCCAGTCAAGTTAATGGGTGCCATGCAGAAGCAACTTGAGCAAAATCA CCTGCAGGGG3'
RT10:5'ATCCGCCTGATTAGCGATACTTATTTGCCCCTGCAGGCCGCAGGAGTGCAGCAGTACTTGAGCAAAATCA CCTGCAGGGG3'
Rknot 1.1: 5'GGGAGAUUCCGUUUUCAGUCGGGAAAAACUGAA3'
Table 2: Sensitivity of aptamer-resistant RTs to NRTIs and NNRTIsAssays were performed as described in the text. Data represent 
mean ± SEM of three independent experiments.
WT N255D N265D Dbl
Inhibitor aIC50, µM bRatio IC50, µMR a t i oI C 50, µMR a t i oI C 50, µMR a t i o
AZTTP 1.83 ± 0.25 1 2.67 ± 0.09 1.45 1.74 ± 0.28 0.9 2.43 ± 0.26 1.3
ddATP 0.93 ± 0.18 1 1.07 ± 0.11 1.2 0.84 ± 0.04 0.9 0.91 ± 0.07 1
ddCTP 0.88 ± 0.20 1 0.69 ± 0.07 0.8 0.72 ± 0.17 0.8 0.96 ± 0.09 1.1
3TCTP 4.37 ± 0.87 1 2.51 ± 1.04 0.6 5.02 ± 1.22 1.1 2.69 ± 0.95 0.6
d4TTP 0.79 ± 0.05 1 0.83 ± 0.14 1 0.64 ± 0.12 0.8 0.91 ± 0.10 1.2
Nevirapine 0.10 ± 0.01 1 0.06 ± 0.02 0.6 0.09 ± 0.03 0.9 0.07 ± 0.01 0.7
Delavirdine 0.37 ± 0.02 1 0.64 ± 0.03 1.7 0.36 ± 0.01 1 0.31 ± 0.01 1
aConcentration of inhibitor at which 50% of the activity was inhibited.
bRatio of this enzyme's drug susceptibility to that of wild type.AIDS Research and Therapy 2005, 2:8 http://www.aidsrestherapy.com/content/2/1/8
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the RNase H domain in addition to previously shown
effect on polymerase domain, both of which are essential
for efficient viral DNA replication.
Results
Cross-resistance of DNA aptamer RT1t49-resistant 
mutants of HIV-1 RT to other inhibitors
We investigated whether the aptamer-resistance muta-
tions, N255D and N265D, would affect the sensitivity of
HIV-1 RT to other DNA and RNA aptamers directed to
HIV-1 RT [21,23]. RT1t49 and 5 other DNA aptamers rep-
resenting each of the six classes of DNA aptamers
described by Schneider et al. [23] and a single RNA
aptamer 1.1 (termed Rknot 1.1 here) were selected. Using
a steady-state nucleotide incorporation assay, a similar
pattern of resistance to that of RT1t49 was observed with
DNA aptamers RT26, RT4, and RT6 (Table 1). In each of
these cases, the N265D mutation conferred a greater
degree of resistance compared to the N255D mutation. In
addition, the presence of both mutations led to an even
greater degree of resistance (6- to 27-fold) to aptamers in
this group. In contrast, both N255D and Dbl mutant RTs
were hypersensitive (10-fold) to DNA aptamer RT8, while
the N265D mutant displayed wild type levels of sensitiv-
ity (Table 1). However, with respect to the DNA aptamer
RT10 and the single RNA aptamer tested (Rknot1.1), the
N255D mutant was similar to wild type, while both
N265D and Dbl mutants were significantly resistant. The
similarity between resistance profiles of N255D and
N265D mutant RTs to both DNA aptamers (RT1t49,
RT26, RT4, RT6) suggest that the residues N255 and N265
are important contacts for several classes of DNA
aptamers.
We next tested cross-resistance of these variant RTs to con-
ventional RT inhibitors such as NRTIs and NNRTIs. Each
of the single mutants, N255D and N265D, and the dou-
ble mutant RTs were tested for their sensitivity to a
selected set of NRTIs (AZTTP, ddATP, ddCTP, d4TTP and
3TCTP) or the NNRTIs (nevirapine and delavirdine).
Interestingly, neither the single mutations nor the double
mutants altered the susceptibility of HIV-1 RT to any of
these RT inhibitors (Table 2).
Some NRTI-resistant RTs display low-level resistance to 
the DNA aptamer, RT1t49
Similar experiments were performed to determine the
effectiveness of the DNA aptamer, RT1t49 in inhibiting
the polymerase activities of several NRTI-resistant
mutants of HIV-1 RT. Variants of HIV-1 RT shown to
confer resistance to AZT (T215Y/M41L) and ddI and ddC
(L74V) were sensitive to inhibition by RT1t49 (Table 3).
In contrast, mutations shown to confer resistance to mul-
tiple NRTIs, including E89G, K65R and M184V displayed
low levels of resistance to RT1t49 (2–5 fold), with K65R
displaying the highest level of resistance (5-fold). K65R is
known to cause resistance to all clinically approved NRTIs
except AZT in patients. However, in vitro biochemical
experiments do show some resistance to AZTTP and it has
been suggested this is due to K65R decreasing the rate of
AZTMP excision. The residues E89 and K65 are located in
template grip region of palm and the β3-β4 hairpin loop
of fingers regions respectively. Both these regions are
known to contact different parts of the template·primer
molecule. Thus, these results suggest that the RT1t49
aptamer may make contact with several of the key regions
of RT involved in template·primer contact.
Anti-HIV RT aptamer-resistant RT mutants are defective 
for RNase H-mediated cleavage
We next tested the impact of aptamer resistance mutations
on RNase H activity associated with HIV-1 RT. Previous
studies have shown that alanine substitutions at several
residues within the minor groove binding track (MGBT)
[27] affect not only RT processivity, but also the specificity
of RNase H-catalyzed removal of the polypurine tract
(PPT) primer [28]. Both N255 and N265 are located in the
α H helix of HIV-1 RT, and are therefore in close proximity
to the MGBT. Both the polymerase-dependent and RNA
5'-end-directed RNase H activity of wild type and
aptamer-resistant RTs were tested. Under conditions that
prevent the RT from rebinding the substrate RNA.DNA
duplex, the aptamer-resistant RTs were found to be defi-
cient in both polymerase-dependent and RNA 5'-end-
directed RNase H activities (Figure 1A and 1B). In this
case, RT was pre-bound to the DNA.RNA substrate before
reactions were initiated by adding both MgCl2  and
heparin as a competitive trap. Therefore any cleavage
products formed were the result of a single binding event.
Polymerase-dependent RNase H cleavage by wild type RT
results in the formation of a 102-nt product (Figure 1A,
lane 1). The smaller 94-nt product is the result of subse-
quent 3' → 5' directional nucleolytic activity of HIV-1 RT
Table 3: Sensitivity of NRTI-resistant RTs to the DNA aptamer 
RT1t49Assays were performed as described previously [34]. 
Data represent mean ± SEM of three independent experiments.
Enzyme IC50, nM Ratio
WT 1.5 ± 0.03 1
E89G 4.9 ± 0.06 3.3
K65R 8.0 ± 0.05 5.3
L74V 0.86 ± 0.02 0.6
M184V 3.2 ± 0.05 2.1
T215Y/M41L 2.1 ± 0.04 1.4
aConcentration of inhibitor at which 50% of the activity was inhibited 
over the IC50 for wild type (WT) RTAIDS Research and Therapy 2005, 2:8 http://www.aidsrestherapy.com/content/2/1/8
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RNase H [29,30]. Under identical conditions, each of the
aptamer-resistant RTs failed to produce significant
amounts of either 102-nt or 94-nt products (Figure 1A,
lanes 2–4). While there appeared to be a limited cleavage
by both N255D and Dbl mutants, products formed were
altered in size compared to wild type products (Figure 1A,
lane 1 vs. lanes 2 and 4). These results indicate that
although the N255D and Dbl mutant RTs possess residual
polymerase-dependent RNase H activity under single
cycle cleavage conditions, the specificity of cleavage under
such conditions has not been retained.
Similar reactions were carried out to determine the effect
of aptamer resistance mutations on HIV-1 RT RNA 5'-end-
RNase H cleavage of RNA.DNA hybrids by wild type (WT) and mutant RTs in the presence of a heparin challenge Figure 1
RNase H cleavage of RNA.DNA hybrids by wild type (WT) and mutant RTs in the presence of a heparin chal-
lenge. A. Polymerase-dependent RNase H clevage. The substrate, as diagrammed at the top, consisted of a 142nt heteropoly-
meric RNA (thin line) annealed to a 30nt DNA primer (thick line). Arrows indicate the expected sites of cleavage. Reactions 
were performed in the absence of dNTPs and in the presence of a heparin trap. Control reactions were performed in which 
either no enzyme was added (C), or an RNAse H-defective mutant (E478Q) was added (RNase H-) (see Methods secion). 
Cleavage products were resolved on a denaturing 6% polyacrylamide gel. The sizes of the resultant radiolabeled products are 
represented to the left of the gel panels (including a minor product). B. RNA 5'-end-directed RNase H cleavage. The substrate 
was a 41nt heteropolymeric RNA annealed to a 47nt DNA template. Reaction conditions were otherwise identical to those in 
panel A, and are described under 'Materials and Methods' section. Cleavage products were resolved on a denaturing 12% poly-
acrylamide gel. The sizes of the resultant radiolabeled products are represented to the left of the gel panels.AIDS Research and Therapy 2005, 2:8 http://www.aidsrestherapy.com/content/2/1/8
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directed RNase H activity (Figure 1B). Following comple-
tion of minus strand DNA synthesis, RNA fragments left
behind are removed by this activity in order to facilitate
plus strand DNA synthesis. Both wild type and aptamer
resistant RTs were incubated with the RNA:DNA substrate
before reactions were initiated by adding MgCl2  and
heparin trap. Wild type RT efficiently cleaved the
RNA:DNA substrate, resulting in the expected 18-nt cleav-
age product in addition to several smaller products that
are the result of processive cleavage. In contrast, reactions
in which aptamer-resistant RTs were included resulted in
minimal cleavage products (Figure 1B, lanes 2–4).
Together, these results indicate that both aptamer resist-
ance mutations N255D and N265D result in a severe
reduction of HIV-1 RT mediated RNase H cleavage under
challenged conditions.
The observed defect in Figure 1 appears to be due to a loss
in substrate affinity and not due to defect in the RNase H
catalytic activity of these mutant RTs. To determine
whether these mutant RTs retained RNase H catalytic
activity, we measured the polymerase-dependent RNase H
cleavage by wild type and mutant RTs in the absence of a
trap. As shown in Figure 2, within a 5-min reaction time,
wild type RT made the expected 102- and 94-nt products.
Unlike the previous challenged RNase H reactions (Figure
1), N255D, N265D, and Dbl mutant RTs were able to
make comparable amounts of polymerase-dependent
RNase H cleavage products (Figure 2). Both the overall
amounts and size distribution of cleavage products were
similar between wild type and mutant RTs under these
conditions. Thus, the aptamer-resistance mutations do
affect RNase H under conditions that require re-binding.
Discussion
Our results highlight several key features of the aptamer-
resistant RTs bearing the mutations N255D, N265D or
both (Dbl). First, each mutant displayed cross-resistance
to three of the 7 anti-RT aptamers tested (Table 1). Inter-
estingly, with three of the aptamers (RT26, RT4 and RT6),
the pattern of resistance was very similar to that seen with
RT1t49 in that the reduction in susceptibility was small in
the case of RTs containing single mutations, and it was
greater for the Dbl mutant. As shown previously, the level
of resistance of each of the RTs to RT1t49 directly corre-
lated with the dissociation constants for this aptamer. In
the absence of changes in affinity to normal tem-
plate·primer substrate, this suggests that the affinity of
the aptamer to the RT determines the degree of inhibition
achieved [25]. Therefore, our results indicate that N255
Comparison of polymerase-dependent RNase H activities of wild type (WT), and mutant RTs Figure 2
Comparison of polymerase-dependent RNase H activities of wild type (WT), and mutant RTs. HIV-1 RT and 
template·primer substrates were combined and time course reactions were performed with a 5'-end labeled 142nt RNA tem-
plate and 30nt DNA primer for 0, 10, 30, 60, 120 and 300 seconds. Cleavage products were resolved by denaturing 6%. The 
product sizes are indicated to the left of the panel.AIDS Research and Therapy 2005, 2:8 http://www.aidsrestherapy.com/content/2/1/8
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and N265 are important contact points by which HIV-1
RT interacts with each of these aptamers. In earlier work,
Schneider et al. [23] classified the 30 different DNA
aptamers they obtained by SELEX into six families based
on primary sequence and the presence of specific second-
ary structures (e.g., stems, loops etc.) [23]. In spite of the
dissimilarity in primary and secondary structures of the
different RT-binding aptamers, it is thought that they all
generate very similar 3-dimensional structures allowing
them to interact with a similar binding surface on the RT
protein. Additional evidence in support of this is the pres-
ence of the characteristic interrupted helices present in all
RT-binding aptamers. The observation that N255D and
N265D mutations confer resistance to aptamers in multi-
ple classes suggests that these aptamers all bind HIV-1 RT
in a similar manner.
The cross-resistance patterns suggest some distinct differ-
ences among the anti-RT aptamers. For example, the lack
of change in sensitivity of N265D mutant to aptamer RT8
(Table 1) suggests that the residue N265 may not play a
key role in binding to RT8. It is also interesting that
N255D mutant displays a 10-fold hypersensitivity to RT8.
We surmise that N255 residue may be involved in binding
to RT8 – however, abrogation of this interaction by the
N255D substitution may result in a conformational
change in the RT8 or RT, which may lead to better interac-
tion with another part of RT thus increasing its affinity to
the mutant RT. Our previous work shows that changes in
sensitivity to inhibition by aptamers for N255D and
N265D mutant RTs directly correlate with their binding
affinities to the aptamer [25]. A similar 10-fold hypersen-
sitivity of Dbl mutant to RT8 appears to reflect the
observation that the effect of N255D is dominant over
that of N265D in the context of both mutations.
A long-term goal of testing anti-RT aptamers is to develop
them as anti-HIV agents to be administered to individuals
who have drug failure due to chronic anti-retroviral treat-
ment or for those under supervised treatment interruption
[10]. Thus, it is highly desirable that aptamers are able to
suppress even drug resistant viruses. Clinically relevant
aptamers can be introduced via gene therapy into hemat-
opoietic cells of HIV-infected patients undergoing antivi-
ral therapy. Therefore, these anti-HIV aptamers will be
expressed intracellularly as RNA. In this report, we have
used a DNA aptamer (RT1t49) as a model to test this
notion. Our results show that most NRTI-resistant RTs dis-
play only mild resistance to aptamers (1 to 2-fold) (Table
3). However, both E89G [31], which rarely occurs among
clinical isolates as a primary mutation and the more com-
monly encountered K65R, both display a modest level of
resistance to RT1t49 (3- to 5-fold). However, both of these
mutant enzymes have been shown to have altered proper-
ties with respect to their interaction with tem-
plate·primer. The K65R and E89G mutants have been
reported to display reductions of 50% and 32% in their
dissociation constants [[32,33],196,215]. Therefore, it is
likely that the increased IC50 of these enzymes to inhibi-
tion by the aptamer RT1t49 is an indirect result of their
decreased dissociation from template·primer. The results
of RT1t49 susceptibility testing (Table 3) with the ddI/
ddC-resistant L74V, 3TC-resistant M184V and the AZT-
resistant T215Y/M41L RTs are in agreement with our pre-
viously published efficacy tests using Jurkat T cell lines
expressing each of the three selected anti-RT RNA aptam-
ers, in which all the RNA aptamers were able to efficiently
suppress replication of drug-resistant HIV [19].
Testing the wild type and the aptamer-resistant mutants of
HIV-1 RT for inhibition by a variety of NRTIs and NNRTIs
revealed that even if aptamer-resistance were to arise in
vivo, such viruses can be efficiently suppressed by conven-
tional antiretrovirals (Table 2). These results would be rel-
evant to a scenario when aptamers are to be administered
to HIV-infected individuals, possibly via hematopoietic
stem cell therapy followed by bone marrow transplanta-
tion. In the event that aptamer-resistant variants would
arise in such patients, standard RTIs can still be used to
treat such patients.
The above observation, however, was tempered by the fact
that some of the NRTI-resistance mutations, such as E89G
and K65R conferred a significant degree of resistance to
RT1t49 (3 to 5-fold). On the one hand, these results
suggest that pre-existing NRTI-resistance mutations, due
to altered affinities to template·primer can confer co-
resistance to aptamers or that mutations such as K65R
could arise in response to aptamer therapy. On the other
hand, the resistance data provides insights into indirect
means by which aptamer-RT interactions can be altered.
Aptamer resistance can result from either a direct disrup-
tion of contact of the mutated residue with the aptamer or
from an indirect effect on the conformation of a
neighboring amino acid residue, increasing the tem-
plate·primer affinity thus indirectly leading to altered sus-
ceptibility to the aptamer.
Although resistance to aptamers can be generated by spe-
cific mutations, our earlier work shows that these muta-
tions alone reduce the virus infectivity by 12- to 30-fold
over wild type in a single round of infection using an LTR-
lacZ reporter cell line [25]. In addition, during a multi-day
replication experiment using CD4 T cells in culture, all
three viruses were unable to replicate and spread through
the culture [25]. Both N255 and N265 are adjacent to the
residues that form the MGBT of HIV-1 RT. The MGBT has
been shown to be critical for translocation of the enzyme
along the template·primer during polymerization [27].
In addition, as shown by our earlier studies, both N255DAIDS Research and Therapy 2005, 2:8 http://www.aidsrestherapy.com/content/2/1/8
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and N265D mutations affected the DNA-dependent DNA
polymerase processivity, while N255D was also defective
for RNA-dependent DNA polymerase processivity [26].
Our current results show that while the gross RNAse H
activity is unaffected under conditions that allow re-bind-
ing (Figure 2), the processive RNAse H activity (under
conditions that prevent re-binding) is affected for all three
mutants (Figure 1). Thus, these mutations appear to
diminish the ability of HIV-1 RT to associate with and uti-
lize its nucleic acid substrate, therefore resulting in multi-
ple functional defects that contribute to loss of replication
fitness for the aptamer-resistant viruses. We believe that
this may help explain our inability to select for resistant
variants using cell lines expressing RNA aptamers (P. Joshi
and V. Prasad, unpublished observations).
Conclusion
The results presented in this report attempt to unravel the
wider significance of the only two mutations previously
known to specifically alter sensitivity to anti-HIV-1 RT
aptamers. The mutations N255D and N265D both con-
ferred resistance to two of the 5 new DNA aptamers (with
the exception of RT8) and 1 RNA aptamer tested suggest-
ing that the N255 and N265 residues probably serve as
contact points for most aptamers. Thus, it is likely that
selection with the other aptamers may also lead to these
same mutations. Interestingly, the mutations N255D or
N265D do not affect sensitivity to any of the NRTIs or
NNRTIs tested which is a useful feature if the same muta-
tions were to arise in response to treatment with anti-RT
aptamer RNAs via gene therapy in the future. Previous
results showed that these two mutations, when reconsti-
tuted into molecular clones of HIV, lead to replication
defective viruses. The effects documented here, on RNase
H function, combined with defects in the processive
synthesis of DNA previously shown, provide additional
rationale for the loss of replication competence for such
viruses.
Methods
Polymerization assays
Sensitivity to inhibition by aptamers, NRTIs and NNRTIs
The sensitivity of wild type and mutant RTs to DNA and
RNA aptamers, NRTIs and NNRTIs was measured in
standard RT reactions essentially as described earlier [34]
with the exception that 16S rRNA (Roche Diagnostics,
Indianapolis, Indiana) annealed to VP200 (5'-TAACCTT-
GCGGCCGTACTCCCC-3') was used as template·primer.
Reaction mixtures (50 µl) contained 24 nM tem-
plate·primer, 80 mM KCl, 50 mM Tris-Cl (pH 8.0), 6 mM
MgCl2, 1 mM dithiothreitol (DTT), 0.1 mg/ml BSA, 10 µM
[α-32P] dGTP or TTP, 25 µM each of the remaining three
dNTPs and a range of concentrations of DNA and RNA
aptamers. Reactions, initiated by the addition of 25ng of
each RT (corresponding to 10, 79, 16 and 28 units respec-
tively for wild type, N255D, N265D and Dbl) were incu-
bated at 37°C for 15 min. IC50 values of each inhibitor for
a given RT variant were determined by fitting results from
at least three independent experiments to a dose-response
curve using nonlinear regression (GraphPad Software
Inc., San Diego) using the following equation:
RNase H Assays
Challenged, polymerase-dependent and RNA 5'-end-directed 
cleavages
To measure the ability of enzymes to cleave RNA:DNA
duplexes as the result of a single binding event, a heparin
trap was added to bind any unbound enzyme or enzyme
dissociated from the duplex following cleavage. Polymer-
ase-dependent reactions included a 30-nt DNA primer
annealed to a 142-nt RNA template [35]. For RNA 5'-end-
directed reactions, a 41-nt RNA primer was annealed to a
47-nt DNA template. In both cases, RNA was 5'-end
labeled using [γ-32P]ATP (3000 Ci/mmol) in the presence
of T4 polynucleotide kinase. Final reaction mixtures (25
µl) contained 25 mM Tris-HCl (pH 8.0), 1 mM DTT, 34
mM KCl, 6 mM MgCl2, 0.5 mM EDTA, 4 nM substrate, 4
mg/ml heparin, and 0.85 nM. The reactions were initiated
with MgCl2, incubated for 15 min at 37°C, and then ter-
minated with 25 µl stop solution. Polymerase-dependent
and RNA 5'-end-directed cleavage products were resolved
using denaturing 6 and 12% PAGE, respectively followed
by phosphorimager analysis. Control reactions were car-
ried out using an RNase H-defective mutant of RT, E478Q
[36] showing no cleavage of the RNA:DNA duplex
Unchallenged, polymerase-dependent cleavages
Similar to challenged reactions, for unchallenged
polymerase-dependent RNAse H reactions, a 30-nt DNA
primer was annealed to a 142-nt RNA template [35]. The
RNA template was 5'-end labelled using [γ-32P]ATP (3000
Ci/mmol) in the presence of T4 polynucleotide kinase.
Reactions (100 µl) were performed under the following
conditions: 3.4 nM RT, 4 nM 5'- [32P]-labeled 142-nt RNA
template annealed to a 30-nt DNA primer, 25 mM Tris-
HCl (pH 8.0), 1 mM DTT, 34 mM KCl, 6 mM MgCl2, and
0.5 mM EDTA. RT was preincubated with the RNA:DNA
substrate in the absence of MgCl2 for 5 min at 37°C. Reac-
tions were initiated by the addition of MgCl2, and at vari-
ous time points (0, 30s, 60s, 120s) an aliquot (25 µl) was
removed and combined with 25 µl stop solution to stop
cleavage. Cleavage products were analyzed by denaturing
6% PAGE. RNase H-directed cleavage was detected by dry-
ing the gels followed by phosphorimager analysis.
Y=
Baseline response +(Maximum response - Baseline response)
1+ + − 10 50 LogEC XAIDS Research and Therapy 2005, 2:8 http://www.aidsrestherapy.com/content/2/1/8
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